SEC Form 4 · accession 0001209191-15-069921
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stuart A Arbuckle
Officer — EVP\Chief Commercial Officer
Period of report
Sep 4, 2015
Accepted (ET)
Sep 9, 2015 · 4:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 4, 2015 | M | 9,063 | $53.74 | A | 136,578 | D | |
| Common StockF2,F3 | Sep 4, 2015 | S | 400 | $124.43 | D | 136,178 | D | |
| Common StockF2,F4 | Sep 4, 2015 | S | 5,200 | $125.42 | D | 130,978 | D | |
| Common StockF2,F5 | Sep 4, 2015 | S | 3,463 | $126.44 | D | 127,515 | D | |
| Common Stock | holding | — | — | — | 140 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F6 | $53.74 | Sep 4, 2015 | M | 9,063 | D | — | Sep 3, 2022 | Common Stock | 9,063 | 18,125 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- F2Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F3Open market sales reported on this line occurred at a weighted average price of $124.43 (range $123.98 to $124.85).
- F4Open market sales reported on this line occurred at a weighted average price of $125.42 (range $124.99 to $125.98).
- F5Open market sales reported on this line occurred at a weighted average price of $126.44 (range $126.00 to $126.92).
- F6The option vests in 16 quarterly installments from 09/04/2012.